|

Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer

RECRUITINGSponsored by Geneplus-Beijing Co. Ltd.
Actively Recruiting
SponsorGeneplus-Beijing Co. Ltd.
Started2026-07-08
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07681323

Summary

This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed advanced breast cancer, molecular subtype HR+/HER2-
* Age ≥18 years
* Expected survival \>3 months
* Willing to undergo ctDNA testing and sign informed consent form

Exclusion Criteria:

* The subject has not signed the informed consent form.
* Pregnant or breastfeeding women.
* Other situations deemed by the investigator as unsuitable for inclusion in the study.

Conditions3

Advanced Breast CancerBreast CancerCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.